KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Other Operating Expenses: 2017-2024

Historic Other Operating Expenses for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $17.9 million.

  • Aquestive Therapeutics' Other Operating Expenses rose 1.56% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year decrease of 4.39%. This contributed to the annual value of $17.9 million for FY2024, which is 14.20% down from last year.
  • As of FY2024, Aquestive Therapeutics' Other Operating Expenses stood at $17.9 million, which was down 14.20% from $20.8 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Other Operating Expenses high stood at $20.8 million for FY2023, and its period low was $13.0 million during FY2020.
  • For the 3-year period, Aquestive Therapeutics' Other Operating Expenses averaged around $19.4 million, with its median value being $19.4 million (2022).
  • Per our database at Business Quant, Aquestive Therapeutics' Other Operating Expenses slumped by 36.33% in 2020 and then rose by 29.33% in 2022.
  • Over the past 5 years, Aquestive Therapeutics' Other Operating Expenses (Yearly) stood at $13.0 million in 2020, then increased by 15.62% to $15.0 million in 2021, then rose by 29.33% to $19.4 million in 2022, then climbed by 7.45% to $20.8 million in 2023, then declined by 14.20% to $17.9 million in 2024.